<i id='6BC326A3CA'><strike id='6BC326A3CA'><tt id='6BC326A3CA'><pre id='6BC326A3CA'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
23andMe had bad news about my health. I wish a person had delivered it 
The biotech scorecard for Q4: 16 stock 
New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum 
Health insurers' Q3 question: how much care are people getting? 
DIEP, the 'gold standard' of breast reconstruction, is under threat 
Stop Congress from blocking public access to science 
Moonlake's readout produced a cash windfall. Risks remain
Health insurers' Q3 question: how much care are people getting?
Moonlake's readout produced a cash windfall. Risks remain 
Brain 'hot spot' may explain why African Americans feel greater pain
DIEP, the 'gold standard' of breast reconstruction, is under threat 
Community addresses injustice for Long Island mothers 
Virginia high school admissions case could be legal follow 
Lawsuit highlights wrinkle for disputes over surprise medical bills 
Hepatitis C has a cure — but many Americans still lack access to it 
